Directly Funded Research and Initiatives
The David M. Blank Foundation directly financially supports these individuals and organizations that align with our mission to advance pancreatic cancer detection and treatment.
The David M. Blank Foundation directly financially supports these individuals and organizations that align with our mission to advance pancreatic cancer detection and treatment.
Dr Elliot K. Fishman is a Professor in the Johns Hopkins Medicine Department Radiology and Radiological Science, Department of Oncology and Department of Surgery. He serves as a member of the Johns Hopkins Kimmel Cancer Center. His clinical research interests focus on medical imaging with specific emphasis on 3D imaging , CT imaging and use of Artificial Intelligence (AI) for the early detection of cancer with a specific focus on pancreatic cancer.
The vision and mission of the Kenner Family Research Fund are dynamic and future-oriented, with a focus on collaboration and information-sharing as a way to make earlier interception of pancreatic cancer a reality.
The David M. Blank Foundation recognizes these individuals and organizations for their vital contributions to the field. While these are independent of our direct funding, we value their commitment to the shared fight against pancreatic cancer.
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors.
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors.
The David M. Blank Foundation is a proud member of the World Pancreatic Coalition (WPCC), an organization dedicated to driving transformational change for those affected by pancreatic cancer. The WPCC is a global network of approximately 120 organizations united in the fight against pancreatic cancer. Only 43 organizations in the entire United States hold WPCC membership, and we are honored to stand among them.
The Coalition brings critical attention to pancreatic cancer and advocates for greater awareness, funding, and research. With an emphasis on early detection, treatment and patient care, the WPCC shares our belief that catching pancreatic cancer earlier is the key to saving lives. Through the WPCC, we will collaborate with leading organizations worldwide who share our commitment to redefining the standard of care and transforming early detection.
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors.
Dr. Matthew Ercolani is one of the leading doctors in the world performing pioneering histotripsy procedures to combat cancerous tumors.
The vision and mission of the Kenner Family Research Fund are dynamic and future-oriented, with a focus on collaboration and information-sharing as a way to make earlier interception of pancreatic cancer a reality.
What are the early warning signs of pancreatic cancer? screening options are available?
How do I access clinical trials support is available?
Where can I find counseling and emotional support?
We also support the Kenner Family Research Fund, who also work to advance early detection of pancreatic cancer to improve survival.
